The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwCLL 2019 | Updates from the ERIC: a focus on MRD-guided approaches
Paolo Ghia, MD, PhD, IRCCS, San Raffaele Scientific Institute, Milan, Italy, delivers updates from the European Research Initiative on CLL (ERIC) where they’ve focused on measurable residual disease (MRD) with a dedicated workshop having been organized. Prof. Ghia also gives an outline of the IMPROVE study of venetoclax in combination with ibrutinib. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.
